Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study. Natasha B. Leighl , Hiroaki Akamatsu , Sun Min Lim , Ying Cheng , Anna R. Minchom , Melina E. Marmarelis , Rachel E. Sanborn , James Chih-Hsin Yang , Baogang Liu , Thomas John , Bartomeu Massuti , Alexander I. Spira , Se-Hoon Lee , Jialei Wang , Juan Li , Caigang Liu , Silvia Novello , Masashi Kondo , Motohiro Tamiya , Ernesto Korbenfeld , Mor Moskovitz , Ji-Youn Han , Mariam Alexander , Rohit Joshi , Enriqueta Felip , Pei Jye Voon , Pongwut Danchaivijitr , Ping-Chih Hsu , Felipe Jose Silva Melo Cruz , Thomas Wehler , Laurent Greillier , Encarnacao Teixeira , Danny Nguyen , Joshua K. Sabari , Angel Qin , Dariusz Kowalski , Mehmet Ali Nahit Sendur , John Xie , Debopriya Ghosh , Ali Alhadab , Nahor Haddish-Berhane , Pamela L. Clemens , Patricia Lorenzini , Remy B. Verheijen , Mohamed Gamil , Joshua M. Bauml , Mahadi Baig , Antonio Passaro JOURNAL OF CLINICAL ONCOLOGY（2024）
AI 理解论文
溯源树
样例
